

Michael R Charlton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6590636/publications.pdf>

Version: 2024-02-01

99
papers

16,457
citations

76031

42
h-index

42259

96
g-index

100
all docs

100
docs citations

100
times ranked

18943
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 1030-1041. | 1.8 | 74 |
| 2 | The Practice of Retransplantation for Recurrent Alcohol-associated Liver Disease in the United States Is Uncommon With Acceptable Outcomes. <i>Transplantation Direct</i> , 2022, 8, e1297. | 0.8 | 2 |
| 3 | Preservation solutions for static cold storage in donation after circulatory death and donation after brain death liver transplantation in the United States. <i>Liver Transplantation</i> , 2022, 28, 1454-1462. | 1.3 | 7 |
| 4 | Relatively Poor Long-term Outcomes Following Liver Transplantation for NASH in the United States. <i>Transplantation</i> , 2022, 106, 2006-2018. | 0.5 | 8 |
| 5 | Simultaneous Heart and Liver Transplantation for Congenital Heart Disease in the United States: Rapidly Increasing With Acceptable Outcomes. <i>Hepatology</i> , 2021, 73, 1464-1477. | 3.6 | 18 |
| 6 | Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency. <i>American Journal of Transplantation</i> , 2021, 21, 1039-1055. | 2.6 | 49 |
| 7 | The demise of islet allotransplantation in the United States: A call for an urgent regulatory update. <i>American Journal of Transplantation</i> , 2021, 21, 1365-1375. | 2.6 | 33 |
| 8 | Living Donor Liver Transplantation in the United States: Evolution of Frequency, Outcomes, Center Volumes, and Factors Associated With Outcomes. <i>Liver Transplantation</i> , 2021, 27, 1019-1031. | 1.3 | 31 |
| 9 | Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. <i>Seminars in Liver Disease</i> , 2021, 41, 225-234. | 1.8 | 37 |
| 10 | “Raising HOPE”: Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era. <i>Transplantation Direct</i> , 2021, 7, e707. | 0.8 | 9 |
| 11 | Mandatory Hepatology Education for Internal Medicine Residents: Long-Term Effects and Implications for Workforce Needs. <i>Hepatology Communications</i> , 2021, 5, 1953-1963. | 2.0 | 0 |
| 12 | Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1198-1208. | 0.8 | 12 |
| 13 | Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. <i>Transplantation</i> , 2021, 105, 1285-1290. | 0.5 | 25 |
| 14 | Nonalcoholic Steatohepatitis After Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 141-159. | 1.3 | 49 |
| 15 | Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G333-G344. | 1.6 | 4 |
| 16 | An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. <i>Journal of Gastroenterology</i> , 2020, 55, 811-823. | 2.3 | 41 |
| 17 | LPCN 1144 Resolves NAFLD in Hypogonadal Males. <i>Hepatology Communications</i> , 2020, 4, 1430-1440. | 2.0 | 8 |
| 18 | Hiding in the Water. <i>New England Journal of Medicine</i> , 2020, 382, 1844-1849. | 13.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. <i>Hepatology</i> , 2020, 72, 315-329. | 3.6 | 131 |
| 20 | Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system. <i>Journal of Gastroenterology</i> , 2020, 55, 722-730. | 2.3 | 13 |
| 21 | Practice Habits, Knowledge, and Attitudes of Hepatologists to Alcohol Use Disorder Medication: Sobering Gaps and Opportunities. <i>Transplantation Direct</i> , 2020, 6, e603. | 0.8 | 11 |
| 22 | En bloc liver and pancreas transplantation after total pancreatectomy with autologous Islet transplantation. <i>European Journal of Translational and Clinical Medicine</i> , 2020, 3, 11-17. | 0.0 | 1 |
| 23 | Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)â€Viremic Donors Into HCVâ€Negative Recipients: Outcomes Following Liver Transplant of HCVâ€Viremic Donors. <i>Hepatology</i> , 2019, 69, 2381-2395. | 3.6 | 103 |
| 24 | Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Directâ€Acting Antiviral Era. <i>Liver Transplantation</i> , 2019, 25, 598-609. | 1.3 | 70 |
| 25 | Liver Allocation Policies in the USA: Past, Present, and the Future. <i>Digestive Diseases and Sciences</i> , 2019, 64, 985-992. | 1.1 | 15 |
| 26 | Simultaneous heart, liver and kidney transplantation: A viable option for heart failure patients with multiorgan failure. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 997-999. | 0.3 | 9 |
| 27 | The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality From Cirrhosis. <i>Hepatology</i> , 2019, 69, 931-933. | 3.6 | 14 |
| 28 | International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. <i>Transplantation</i> , 2018, 102, 727-743. | 0.5 | 178 |
| 29 | FGF-19 agonism for NASH: a short study of a long disease. <i>Lancet, The</i> , 2018, 391, 1124-1126. | 6.3 | 6 |
| 30 | Improvement of hepatic fibrosis and patientâ€reported outcomes in nonâ€alcoholic steatohepatitis treated with selonsertib. <i>Liver International</i> , 2018, 38, 1849-1859. | 1.9 | 72 |
| 31 | The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 67, 328-357. | 3.6 | 4,738 |
| 32 | The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. <i>Hepatology</i> , 2018, 67, 549-559. | 3.6 | 435 |
| 33 | Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2018, 22, 201-211. | 1.0 | 65 |
| 34 | Surgical Issues in NASH: Bariatric Surgery and Liver Transplantation. <i>Current Hepatology Reports</i> , 2018, 17, 367-376. | 0.4 | 1 |
| 35 | DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. <i>JCI Insight</i> , 2018, 3, . | 2.3 | 47 |
| 36 | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. <i>World Journal of Gastroenterology</i> , 2018, 24, 1321-1331. | 1.4 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Risk of Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis. <i>Gastroenterology and Hepatology</i> , 2018, 14, 247-249. | 0.2 | 3 |
| 38 | Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. <i>Gastroenterology</i> , 2017, 152, 1090-1099.e1. | 0.6 | 487 |
| 39 | Predictors of Cardiovascular Events After Liver Transplantation. <i>Clinics in Liver Disease</i> , 2017, 21, 367-379. | 1.0 | 15 |
| 40 | A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, G666-G680. | 1.6 | 55 |
| 41 | Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation. <i>Transplantation</i> , 2017, 101, 2873-2882. | 0.5 | 46 |
| 42 | Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 421-430.e6. | 2.4 | 72 |
| 43 | The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. <i>Hepatology</i> , 2016, 64, 19-22. | 3.6 | 174 |
| 44 | Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. <i>Gastroenterology</i> , 2016, 151, 633-636.e3. | 0.6 | 19 |
| 45 | Alcoholic Liver Disease and Liver Transplantation. <i>Clinics in Liver Disease</i> , 2016, 20, 521-534. | 1.0 | 15 |
| 46 | Nonalcoholic Fatty Liver Disease and Liver Transplantation. <i>Clinics in Liver Disease</i> , 2016, 20, 403-417. | 1.0 | 12 |
| 47 | Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells. <i>Journal of Hepatology</i> , 2016, 65, 334-343. | 1.8 | 73 |
| 48 | Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 122-132. | 3.7 | 63 |
| 49 | Roadmap for improving patient and graft survival in the next 10 years. <i>Liver Transplantation</i> , 2016, 22, 71-78. | 1.3 | 19 |
| 50 | On-Treatment HCV RNA in Patients with Varying Degrees of Fibrosis and Cirrhosis in the SOLAR-1 Trial. <i>Antiviral Therapy</i> , 2016, 21, 541-546. | 0.6 | 9 |
| 51 | A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. <i>Hepatology</i> , 2016, 63, 634-643. | 3.6 | 35 |
| 52 | Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management. <i>Gastroenterology</i> , 2016, 150, 1849-1862. | 0.6 | 24 |
| 53 | Usefulness of Liver Transplantation in the Elderly: The Converging Impact of Risk and Benefit. <i>Gastroenterology</i> , 2016, 150, 306-309. | 0.6 | 8 |
| 54 | Practice patterns in NAFLD and NASH: real life differs from published guidelines. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 4-12. | 1.4 | 72 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes. <i>Gastroenterology</i> , 2016, 150, 956-967. | 0.6 | 373 |
| 56 | Reply. <i>Hepatology</i> , 2015, 61, 1442-1443. | 3.6 | 0 |
| 57 | Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. <i>BMC Infectious Diseases</i> , 2015, 15, 371. | 1.3 | 31 |
| 58 | Genetic susceptibility to hepatitis E viral infection: An enigmatic virus gives up a secret. <i>Hepatology</i> , 2015, 62, 1337-1338. | 3.6 | 2 |
| 59 | Response to Fibrosis progression in patients treated for hepatitis C recurrence. <i>Liver International</i> , 2015, 35, 2625-2625. | 1.9 | 0 |
| 60 | Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. <i>Liver International</i> , 2015, 35, 2433-2441. | 1.9 | 27 |
| 61 | An Update of Liver Transplantation for Nonalcoholic Steatohepatitis. <i>Current Hepatology Reports</i> , 2015, 14, 99-108. | 0.4 | 0 |
| 62 | Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015, 149, 649-659. | 0.6 | 725 |
| 63 | Lack of Survival Benefit Following Liver Transplantation With MELD Exception Points for Hepatocellular Carcinoma: Beyond the Unblinding of Lady Justice. <i>Gastroenterology</i> , 2015, 149, 531-534. | 0.6 | 3 |
| 64 | Lack of Health Insurance Limits the Benefits of Hepatitis C Virus Screening: Insights from the National Health and Nutrition Examination Hepatitis C Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2015, 110, 1126-1133. | 0.2 | 29 |
| 65 | Victory and defeat at Heraclea – Treating hepatitis C infection following liver transplantation with telaprevir and boceprevir. <i>Journal of Hepatology</i> , 2014, 60, 6-8. | 1.8 | 5 |
| 66 | The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010. <i>Journal of Hepatology</i> , 2014, 60, 691-698. | 1.8 | 145 |
| 67 | Improving Long-Term Outcomes After Liver Transplantation. <i>Clinics in Liver Disease</i> , 2014, 18, 717-730. | 1.0 | 24 |
| 68 | Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C. <i>Mayo Clinic Proceedings</i> , 2014, 89, 595-601. | 1.4 | 3 |
| 69 | How important is acute cellular rejection?. <i>Liver Transplantation</i> , 2013, 19, S9-S13. | 1.3 | 13 |
| 70 | ChREBP in NASH – A liver transcription factor comes in from the cold. <i>Journal of Hepatology</i> , 2013, 59, 178-179. | 1.8 | 6 |
| 71 | Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. <i>Current Opinion in Organ Transplantation</i> , 2013, 18, 251-258. | 0.8 | 46 |
| 72 | The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>Hepatology</i> , 2012, 55, 2005-2023. | 3.6 | 2,935 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States. <i>Gastroenterology</i> , 2011, 141, 1249-1253. | 0.6 | 1,006 |
| 74 | Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G825-G834. | 1.6 | 357 |
| 75 | A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. <i>Liver Transplantation</i> , 2011, 17, 1394-1403. | 1.3 | 96 |
| 76 | Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. <i>Hepatology</i> , 2011, 53, 317-324. | 3.6 | 204 |
| 77 | Boceprevir (Victrelis) for HCV: V is for victory and very complex. <i>Hepatology</i> , 2011, 54, 1882-1886. | 3.6 | 5 |
| 78 | Pretransplant serum troponin levels are highly predictive of patient and graft survival following liver transplantation. <i>Liver Transplantation</i> , 2010, 16, 990-998. | 1.3 | 37 |
| 79 | Differential expression of lumican and fatty acid binding protein-1: New insights into the histologic spectrum of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2009, 49, 1375-1384. | 3.6 | 122 |
| 80 | Medical hurricane: Health care reform and hepatology. <i>Hepatology</i> , 2009, 50, 1339-1340. | 3.6 | 1 |
| 81 | Obesity, hyperlipidemia, and metabolic syndrome. <i>Liver Transplantation</i> , 2009, 15, S83-S89. | 1.3 | 62 |
| 82 | Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. <i>Hepatology</i> , 2008, 47, 484-492. | 3.6 | 99 |
| 83 | Noninvasive Indices of Fibrosis in NAFLD: Starting to Think About a Three-Hit (At Least) Phenomenon. <i>American Journal of Gastroenterology</i> , 2007, 102, 409-411. | 0.2 | 13 |
| 84 | Branched-Chain Amino Acid Enriched Supplements as Therapy for Liver Disease. <i>Journal of Nutrition</i> , 2006, 136, 295S-298S. | 1.3 | 144 |
| 85 | Branched-chain amino-acid granules: can they improve survival in patients with liver cirrhosis?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2006, 3, 72-73. | 1.7 | 6 |
| 86 | Recurrence of hepatitis C infection: Where are we now?. <i>Liver Transplantation</i> , 2005, 11, S57-S62. | 1.3 | 38 |
| 87 | Natural History and Management of Hepatitis C Infection After Liver Transplantation. <i>Seminars in Liver Disease</i> , 2004, 24, 79-88. | 1.8 | 38 |
| 88 | Nonalcoholic fatty liver disease: A review of current understanding and future impact. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 1048-1058. | 2.4 | 332 |
| 89 | Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. <i>Liver Transplantation</i> , 2003, 9, S58-S62. | 1.3 | 63 |
| 90 | Natural history of hepatitis C and outcomes following liver transplantation. <i>Clinics in Liver Disease</i> , 2003, 7, 585-602. | 1.0 | 51 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Apolipoprotein synthesis in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2002, 35, 898-904. | 3.6 | 271 |
| 92 | Pre-emptive treatment of recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2002, 8, S50-S54. | 1.3 | 8 |
| 93 | Recurrent autoimmune hepatitis after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2001, 7, 302-310. | 1.3 | 185 |
| 94 | Genotype 1b and severity of posttransplant recurrence of hepatitis C infection? unconvictable felon or wrongly accused?. <i>Liver Transplantation</i> , 2000, 6, 243-245. | 1.3 | 10 |
| 95 | Utility of Standard Nutritional Parameters in Detecting Body Cell Mass Depletion in Patients With End-Stage Liver Disease. <i>Liver Transplantation</i> , 2000, 6, 575-581. | 1.3 | 127 |
| 96 | COMPARATIVE ALLOGRAFT HISTOLOGY AFTER LIVER TRANSPLANTATION FOR CRYPTOGENIC CIRRHOSIS, ALCOHOL, HEPATITIS C, AND CHOLESTATIC LIVER DISEASES ¹ . <i>Transplantation</i> , 2000, 70, 292-297. | 0.5 | 67 |
| 97 | Recurrent and new hepatitis C virus infection after liver transplantation. <i>Hepatology</i> , 1999, 29, 1220-1226. | 3.6 | 116 |
| 98 | Predictors of patient and graft survival following liver transplantation for hepatitis C. <i>Hepatology</i> , 1998, 28, 823-830. | 3.6 | 555 |
| 99 | TT-virus infection in north american blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. <i>Hepatology</i> , 1998, 28, 839-842. | 3.6 | 270 |